Caplin Point Laboratories Limited

NSE CAPLIPOINT.NS

Caplin Point Laboratories Limited Goodwill for the year ending March 31, 2024: USD 332.10 K

Caplin Point Laboratories Limited Goodwill is USD 332.10 K for the year ending March 31, 2024, a -1.46% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Caplin Point Laboratories Limited Goodwill for the year ending March 31, 2023 was USD 337.03 K, a 5,018.09% change year over year.
Caplin Point Laboratories Limited Goodwill for the year ending March 31, 2022 was USD 6.58 K, a -10.21% change year over year.
Caplin Point Laboratories Limited Goodwill for the year ending March 31, 2021 was USD 7.33 K, a 2.92% change year over year.
Caplin Point Laboratories Limited Goodwill for the year ending March 31, 2020 was USD 7.13 K, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NSE: CAPLIPOINT.NS

Caplin Point Laboratories Limited

CEO	Dr. Sridhar Ganesan
IPO Date	June 23, 2014
Location	India
Headquarters	Ashvich Tower
Employees	3,406
Sector	Consumer Discretionary
Industries Cosmetics Cleaning Supplies Consumer Packaged Goods Drugstores & Retail Pharmacies Eyewear Perfumes & Fragrances Personal Care Pharmaceuticals

Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

Key trends

Past 5 years